Terazosine [Inn-French]

Terazosine [Inn-French] Brand names, Terazosine [Inn-French] Analogs

Terazosine [Inn-French] Brand Names Mixture

No information avaliable

Terazosine [Inn-French] Chemical_Formula

C₁₉H₂₅N₅O₄

Terazosine [Inn-French] RX_link

http://www.rxlist.com/cgi/generic/teraz.htm

Terazosine [Inn-French] fda sheet

Terazosine_[Inn-French] FDA

Terazosine [Inn-French] msds (material safety sheet)

Terazosine [Inn-French] Synthesis Reference

M. Winn et al., U.S. Pat. 4,026,894 (1977)

Terazosine [Inn-French] Molecular Weight

387.433 g/mol

Terazosine [Inn-French] Melting Point

273 ^oC

Terazosine [Inn-French] H₂O Solubility

29.7mg/mL

Terazosine [Inn-French] State

Solid

Terazosine [Inn-French] LogP

0.875

Terazosine [Inn-French] Dosage Forms

Tablet

Terazosine [Inn-French] Indication

For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.

Terazosine [Inn-French] Pharmacology

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an alpha-adrenergic blocking agent, terazosin is used to treat hypertension and benign prostatic hypertrophy (BPH). Terazosin produces vasodilation and reduces peripheral resistance but in general has slight effect on cardiac output. Antihypertensive effect with chronic dosing is usually not accompanied by reflex tachycardia.

Terazosine [Inn-French] Absorption

Essentially completely absorbed in man (90% bioavailability).

Terazosine [Inn-French] side effects and Toxicity

LD₅₀=259.3mg/kg (i.v. in mice)

Terazosine [Inn-French] Patient Information

Terazosine [Inn-French] Organisms Affected

Humans and other mammals